Calendario›REGN›REGN7075 · COMBINE-EGFR-1

REGN7075 · COMBINE-EGFR-1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Ensayo de REGENERON PHARMACEUTICALS, INC. en Tumor solido avanzado.

Más ensayos de: Tumor sólido avanzado.

Fase

Fase 1/2

Estado

En marcha, sin reclutar

Participantes

548

previstos

Centros

54

Fin del objetivo primario

nov 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2020.

Qué mide

The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period (del registro, en inglés) (hasta 6 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04626635), actualizada en jun 2026.